HomeCompareAITXD vs JNJ

AITXD vs JNJ: Dividend Comparison 2026

AITXD yields 4048.58% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AITXD wins by $8061531857256.39M in total portfolio value
10 years
AITXD
AITXD
● Live price
4048.58%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8061531857256.42M
Annual income
$7,687,983,219,612,022,000.00
Full AITXD calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AITXD vs JNJ

📍 AITXD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAITXDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AITXD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AITXD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AITXD
Annual income on $10K today (after 15% tax)
$344,129.55/yr
After 10yr DRIP, annual income (after tax)
$6,534,785,736,670,218,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AITXD beats the other by $6,534,785,736,670,214,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AITXD + JNJ for your $10,000?

AITXD: 50%JNJ: 50%
100% JNJ50/50100% AITXD
Portfolio after 10yr
$4030765928628.22M
Annual income
$3,843,991,609,806,013,400.00/yr
Blended yield
95.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AITXD
No analyst data
Altman Z
-15.4
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AITXD buys
0
JNJ buys
0
No recent congressional trades found for AITXD or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAITXDJNJ
Forward yield4048.58%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8061531857256.42M$30.3K
Annual income after 10y$7,687,983,219,612,022,000.00$4,689.40
Total dividends collected$8036062888182.31M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AITXD vs JNJ ($10,000, DRIP)

YearAITXD PortfolioAITXD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$415,558$404,858.30$10,592$272.30+$405.0KAITXD
2$16,168,220$15,723,572.58$11,289$357.73+$16.16MAITXD
3$589,038,841$571,738,845.21$12,123$472.89+$589.03MAITXD
4$20,097,119,938$19,466,848,378.98$13,141$629.86+$20097.11MAITXD
5$642,232,524,688$620,728,606,353.73$14,408$846.81+$642232.51MAITXD
6$19,225,768,320,335$18,538,579,518,919.37$16,021$1,151.60+$19225768.30MAITXD
7$539,233,159,841,758$518,661,587,738,999.50$18,122$1,588.22+$539233159.82MAITXD
8$14,172,417,177,673,084$13,595,437,696,642,402.00$20,930$2,228.20+$14172417177.65MAITXD
9$349,110,876,303,174,100$333,946,389,923,063,900.00$24,792$3,191.91+$349110876303.15MAITXD
10$8,061,531,857,256,418,000$7,687,983,219,612,022,000.00$30,274$4,689.40+$8061531857256.39MAITXD

AITXD vs JNJ: Complete Analysis 2026

AITXDStock

Artificial Intelligence Technology Solutions Inc. engages in the delivery of artificial intelligence and robotic solutions for operational, security, and monitoring needs in the United States. The company offers ROAMEO, an autonomous, mobile security robotic vehicle designed to patrol large outdoor spaces; RADDOG LE2, a wheeled, four-legged robotic platform developed for law enforcement and tactical applications; and HERO, a humanoid security robot. It also provides AVA, a gate security solution that manages vehicle entry using AI-powered license plate recognition, two-way voice interaction, and cloud-based authorization; TOM, an AI-powered solution that automates visitor management and front desk functions; and RADCam, an AI-powered, voice-enabled security camera designed for homeowners, property managers, and small businesses. In addition, the company provides ROSA, a compact, self-contained security device that provides autonomous deterrence, detection, and response; RAM, a hardware module that transforms existing IP security cameras into interactive devices; RIO, a portable, solar-powered security tower that includes a single or dual ROSA unit mounted atop a solar panel trailer; and RADCam, a voice-enabled security camera designed for homeowners, property managers, and small businesses. Further, it offers SARA, a voice and decision-making platform; Firearm Detection, an AI-based analytic that identifies visible handguns and guns in real time; and ROSS which enables immediate response and alert escalation the moment a threat is recognized. The company was formerly known as On The Move Systems Corp. and changed its name to Artificial Intelligence Technology Solutions Inc. in August 2018. Artificial Intelligence Technology Solutions Inc. was founded in 2016 and is based in Ferndale, Michigan.

Full AITXD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AITXD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AITXD vs SCHDAITXD vs JEPIAITXD vs OAITXD vs KOAITXD vs MAINAITXD vs ABBVAITXD vs MRKAITXD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.